Endocrine Abstracts

Introduction: Previous studies demonstrated a relationship between T1- and T2-weighted signal intensity and tumor growth pattern in pituitary somatotropinomas. The goal of this retrospective study was to analyze the MRI characteristics of pituitary macroadenomas with different hormonal activity in newly diagnosed patients.Material and methods: Pre-treatment T1- and T2-weighted MR-images (Intera Achieva, PHILIPS, 3.0T) of patients with 42 non-functional a...

Our Pituitary Tumour Registry includes data about 346 patients with pituitary macroadenomas: 142 non-functional adenomas (NFA) including 18 (12.7%) giant, 62 macroprolactinomas – 6 (9.7%) giant, 141 somatotropinomas – 6 (4.3%) giant. We analysed clinical features of these 30 giant pituitary tumors (<40 mm at least one of the sizes): 18 NFA (11 Females; 7 Males), 6 prolactinomas (3 Females; 3 Males), 6 somatotropinomas (3 Females; 3 Males). Patients with giant NFA...

There are some data concerning high prevalence of infrasellar extension of somatotropinomas. To reveal any differences expansion of pitutary macroadenomas with various hormonal secretion, we have analyzed MRI data of 175 pituitary macroadenomas: 87 non-functioning adenomas (NFAs), 48 prolactinomas, 43 somatotropinomas. The sizes of pituitary tumour (vertical, sagittal, frontal): NFAs 24 (17.5; 34.5)mm, 23 (17.4; 28) mm, 23 (18; 30) mm; prolactinomas 21 (15; 31) mm, 20 (16; 30)...

We analysed BMI of 270 female patients: 148 with hyperprolactinaemia (non-tumoural hyperprolactinaemia, n=46; microadenomas, n=56; and macroadenomas, n=46), 55 with isolated central hypogonadism, 67 with hypopituitarism. Additionally, 53 healthy women of reproductive age and 51 postmenopausal women were examined. In patients with hyperprolactinaemia median prolactin levels were 1547 (1124; 2185), 1490 (1050; 2280), and 3100 (1790; 18840) mE/l, accord...

We investigated 49 patients with non-functioning pituitary macroadenomas: 11 males, 38 females, age 31–78 y.o. (median 61). Extrasellar tumor expansion was observed in 46 (93.9%) patients: suprasellar – 41 (83.7%), laterosellar 27 (55.1%), and infrasellar 18 (36.7%) patients; combined types of extrasellar expansion – 36 (73.5%) patients.Prolactin levels (PRL) varied from 115 to 1495 mU/l, hyperprolactinemia was found in 27 (55.1%) patients...

We analyzed data of 148 patients (125 female, 23 male) with hyperprolactinemia who had been investigated in our Department during 2008–2012: Nontumor hyperprolactinemia (NT, n=46, 31%), microadenomas (MI, n=56, 38%), MAcroadenomas (MA, n=46, 31%). Patients’ age was 36 (24; 46), 37 (26; 44) and 49 (33; 60) years respectively. Men were younger than women (P=0.002). Portion of men was higher in MA than in NT and MI: 19% vs 10...

In purpose to characterize the disturbances of menstrual function in acromegalic women of reproductive age, we investigated 19 women with de novo acromegaly diagnosed at the age of 19–37 (median age 28) years. Before diagnosis, an average duration of acro-signs was 3.8 years, after diagnosis we observed women for 5 years. Among the first meaningful symptoms menstrual irregularities and/or infertility were noted in 13 (73.7%) cases. Initial levels of GH were 71 (3...